2022, Abbott has received the U.S. Food and Drug Administration for its EnSite X EP System with EnSite Omnipolar Technology (OT). It is a new cardiac mapping platform available in the US and across Europe that is designed to help physicians better treat abnormal heart rhythms…
Read More
About The Author
